Nanosphere Health SciencesNSHSF Return-on-Tangible-Equity is Negative Tangible Equity% as of Dec. 2025. Among 1,196 Biotechnology companies, Nanosphere Health Sciences ranks worse than 83611.96% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Nanosphere Health Sciences's annualized net income for the quarter that ended in Dec. 2025 was $0.16 Mil. Nanosphere Health Sciences's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $-1.36 Mil. Therefore, Nanosphere Health Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was Negative Tangible Equity%.
The historical rank and industry rank for Nanosphere Health Sciences's Return-on-Tangible-Equity or its related term are showing as below:
NSHSF's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.19 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Nanosphere Health Sciences (OTCPK:NSHSF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Nanosphere Health Sciences Return-on-Tangible-Equity Related Terms
Nanosphere Health Sciences Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanosphere Health Sciences Return-on-Tangible-Equity Chart
NSHSF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Nanosphere Health Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosphere Health Sciences Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanosphere Health Sciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Nanosphere Health Sciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of Negative Tangible Equity% mean?
Nanosphere Health Sciences (NSHSF) has a Return-on-Tangible-Equity of Negative Tangible Equity% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Nanosphere Health Sciences and its competitors. According to the industry distribution chart, Nanosphere Health Sciences ranks #999999 out of 1196 companies in the Biotechnology industry.
Is Nanosphere Health Sciences' Return-on-Tangible-Equity too high?
Nanosphere Health Sciences' current Return-on-Tangible-Equity is Negative Tangible Equity%. Based on the distribution chart, Nanosphere Health Sciences ranks #999999 out of 1196 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Nanosphere Health Sciences' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanosphere Health Sciences ranks #999999 out of 1196 companies for Return-on-Tangible-Equity. This places Nanosphere Health Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Nanosphere Health Sciences and its competitors. Nanosphere Health Sciences's current Return-on-Tangible-Equity is Negative Tangible Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosphere Health Sciences stock overvalued right now?
Nanosphere Health Sciences (NSHSF) has a current Return-on-Tangible-Equity of Negative Tangible Equity%. The current Return-on-Tangible-Equity is Negative Tangible Equity%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Nanosphere Health Sciences (NSHSF), the current Return-on-Tangible-Equity is Negative Tangible Equity% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nanosphere Health Sciences Inc is a biotechnology company focused on providing next generation delivery of biologically active compounds through licensing and joint venture arrangements. The Company has developed and is commercializing its patented NanoSphere Delivery System, a nanotechnology platform for the delivery of biological agents such as cannabinoids, supplements, nutraceuticals, and over-the-counter medications for the cannabis, pharmaceutical, and animal health industries. The NanoSphere Delivery System provides improved bioavailability, efficacy, and onset of effect over traditional delivery systems.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSHSF has been successfully added to your 